Injection Laryngoplasty Using Autologous Fat Enriched With Adipose Derived Regenerative Stem Cells (ADRC)

This is the first Development Safety Update Report prepared for Phase I-IIA Clinical Trial- FIBHGM-ECNC007-2010 (PHASE I / IIA CLINICAL TRIAL, UNICENTRIC, RANDOMIZED, CONTROLLED, TWO PARALLEL-GROUPS, TO EVALUATE THE SAFETY OF A NEW THERAPY WITH STEM CELLS DERIVED FROM ADIPOSE TISSUE FOR GLOTTAL GAP IN THE UNILATERAL PARALYSIS OF THE VOCAL CORD in the International Conference on Harmonization (ICH) E2F format. This trial contains relevant safety information from the reporting interval of 08 July 2012 to 30 Sep 2014 This phase I / IIA clinical trial has been conducted to evaluate the safety of ADRCs. This new therapy is performed to induce the overexpression and production of microvessels in the paralyzed vocal cord, to permanently increase its volume and thus facilitate the GG closure. In paralysis of VC an increase of glottal gap occurs leading to dysphonia and aspiration of food, foreign bodies...

The creation of these new blood vessels, through the action of stem cells derived from adipose tissue, may produce a greater volume of the paralyzed vocal cord allowing GG closure more easily.

Patients included in this clinical trial require treatment for unilateral vocal cord paralysis. It has been considered regarding the authorised protocol that a glottal GAP requires intracordal injection to increase its volume when the glottal closure·during phonation is insufficient or there is lack of compensation to the contralateral vocal cord.

Patients are randomized to receive one of the following therapeutic strategies:

Group A: Autologous Fat processed by centrifugation to fill a paralyzed vocal cord, using the same.

Group B: Autologous Fat enriched with stem cells from adipose tissue to treat vocal cord paralysis.

Active control: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.

Experimental drug: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.

In patients assigned to ADRC group therapy, two surgical interventions are performed on the same day, once randomized, at visit 0 according to the protocol. For the group assigned to the control (autologous adipose tissue), the therapy is performed in a single surgical intervention, once randomized, at visit 0 according to protocol.

The patients who are included will be followed for six months from the implant.

Inclusion criteria

• VC paralysis in paramedian position.
• Patients without previous compensation of the healthy contralateral VF.
• Males and females 18-years old or older.
• Women presenting the possibility of being pregnant must present a negative test of current pregnancy before the inclusion in the clinical trial (it must be certified at the minus 2 medical visit). It can be done by a blood test or a urinary test.
• The paralyzed VC should not be affected by granulomas, tumors o macroscopic objectable lesions by conventional laryngoscopy.
• The clinical situation of the patient must be ASA I or II following the parameters of the American Society of Anesthesiologists.
• There should not be any circumstance that could not afford the patient to follow the procedures of the clinical trial at least 6 months from the operation day.
• The patient must sign and confirm a specific informed acceptance to participate in the trial

Exclusion criteria

• Patients affected by kidney insufficiency, presenting a seric creatinine higher than 2.5 mg/dl.
• Medical history of allergy to proteins, or other allergies that could lead to a safety problem if the patient joins the present clinical trial.
• Acute infectious disease at the moment of enrollment.
• Chronic infectious disease affecting directly or indirectly the anatomical area that is going to be operated (it includes tuberculosis, brucellosis, chronic candidiasis and cutaneous chronic ulcers).
• Pregnancy or lactating patient.
• Patient needing a surgery in the anatomical area that is going to be operated on for a different reason at the moment of inclusion in the study, or patients in which it is suspected to perform surgeries in the mentioned anatomical area 24 weeks after the implant.
• Alcohol abuse or drugs abuse 6 months before the inclusion.
• Latent or active HIV infection or viral hepatitis.
• Patient suffered a major surgery or a major trauma 28 days before enrollment.
• Patients treated with immune-modulators (including therapy with systemic stem cells) 6 months before the inclusion in the study.
• Lung or heart disease that is unstable of presents a gravity that suggests to exclude the enrollment in the study.
• Life expectancy inferior to one year, in relation to comorbidities presenting in the moment of the clinical evaluation.
• Patients presenting deep venous thrombosis or lung thromboembolism, or patients who presented these diseases 6 months before the inclusion in the study.
• Patient presenting acquired or congenital immunodeficiencies.
• Patients presenting hemorrhagic diseases with INR>2,0, without anticoagulant treatment.
• Patients with any medical or psychiatric disorder that under the point of view of the researchers justifies the exclusion in the trial, because follow-up could be interrupted, because enrolment could be a risk for the patient or because it could be a risk for the global evaluation of the clinical trial.
• Patients enrolled currently in other clinical trials, or patients that participated in clinical trial 30 days before the inclusion in this study, if the previous one could not interfere in the participation or in the evaluation of the objectives of the present study.
• Patient who does not wish or cannot follow the procedures indicated in the clinical trial.
• Patients treated with platelet anti-aggregates or non-steroid anti-inflammatories 15 days before the surgery.